Aim: The aim of the study was to evaluate the correlation between renal function and heart function/echocardiographic parameters and epicardial adipose tissue thickness (EATT), respectively.
Material and methods: Fifty patients with type 2 diabetes (T2D) were included in this study. Several laboratory parameters were obtained (HbA1c, fasting blood glucose, LDL-cholesterol, creatinine) and eGFR was calculated. Anthropometric measurements were performed (weight, waist and hip circumferences, 4 skinfolds, based on which % body fat was calculated). Patients underwent echocardiographic assessment to evaluate structural and functional parameters, including EATT. Left ventricular mass (LVM) was calculated and the geometric changes of the left ventricle were evaluated.
Results: Forty-six per cent of the patients had a LV ejection fraction (EF) <55% and 34% had diastolic dysfunction. There were no significant differences between the three eGFR groups with regards to metabolic parameters, but LVEF was lower (53.0 ± 0.8%, 54.4 ± 2.4%, and 55.2 ± 1.5%, respectively) and EATT was higher (11.0 ± 1.0 mm, 8.58 ± 2.2 mm, and 7.63 ± 2.6 mm, respectively) with a lower eGFR (p = 0.04). More patients with eGFR <90 mL/min/1.73 m2 had cardiac hypertrophy compared with those with eGFR ≥90 mL/min/1.73 m2 (p = 0.04). EATT correlated positively with several anthropometric parameters, e.g. weight (r = 0.309, 95% CI: 0.022 to 0.549, p = 0.03), BMI (r = 0.398, 95% CI: 0.123 to 0.616, p = 0.004), and negatively with LVEF (r = −0.496, 95% CI: −0.687 to −0.242, p = 0.0003) and eGFR (r = −0.293, 95% CI: −0.531 to −0.013, p = 0.04). In patients with LVEF <55% vs. ≥55%, the EATT was significantly higher (9.5 ± 1.99 mm vs. 7.33 ± 2.37 mm, p = 0.013).
Conclusion: In patients with T2D decreased renal function was associated with lower LVEF and higher EATT. EATT was also higher in patients with reduced LVEF.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Cernea S. Heart failure and chronic kidney disease in type 2 diabetes. Journal of Interdisciplinary Medicine. 2016;1:252-258.
2. Battiprolu PK Gillette TG Wang ZV et al. Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. Drug Discov Today Dis Mech. 2010;7:e135-e143.
3. McMurray JJ Gerstein HC Holman RR et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843-851.
4. Matloch Z Kotulák T Haluzík M. The role of epicardial adipose tissue in heart disease. Physiol Res. 2016;65:23-32.
5. Wang CP Hsu HL Hung WC et al. Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol (Oxf). 2009;70:876-882.
6. Iacobellis G Barbaro G Gerstein HC. Relationship of epicardial fat thickness and fasting glucose. Int J Cardiol. 2008;128:424-426.
7. Nakanishi K Fukuda S Tanaka A et al. Epicardial Adipose Tissue Accumulation Is Associated With Renal Dysfunction and Coronary Plaque Morphology on Multidetector Computed Tomography. Circ J. 2016;80:196-201.
8. Doesch C Haghi D Flüchter S et al. Epicardial adipose tissue in patients with heart failure. J Cardiovasc Magn Reson. 2010;12:40.
9. American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017;40(Suppl 1):S1-S135.
10. Laborator Synevo. Referintele specifice tehnologiei de lucru utilizate. Available at: https://www.synevo.ro/hemoglobina-glicata-hb-a1c/
11. Laborator Synevo. Referintele specifice tehnologiei de lucru utilizate. Available at: https://www.synevo.ro/colesterol-ldl/
12. Laborator Synevo. Referintele specifice tehnologiei de lucru utilizate. Available at: https://www.synevo.ro/creatinina-serica/
13. Levey AS Stevens LA Schmid CH et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009;150:604-612.
14. Durnin J Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974;32:77–97.
15. Nagueh SF Smiseth OA Appleton CP et al. ASE/EACVI GUIDELINES AND STANDARDS. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321-1360.
16. Marwick TH Gillebert TC Aurigemma G et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging. 2015;16:577-605.
17. Boonman-de Winter LJ Rutten FH Cramer MJ et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154-2162.
18. Henry RM Paulus WJ Kamp O et al. Deteriorating glucose tolerance status is associated with left ventricular dysfunction--the Hoorn Study. Neth J Med. 2008;66:110-117.
19. Boudina S Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213–3223.
20. Ojji DB Adebiyi AA Oladapo OO et al. Left ventricular geometric patterns in normotensive type 2 diabetic patients in Nigeria: an echocardiographic study. Prev Cardiol. 2009;12:184-188.
21. De Jong KA Czeczor JK Sithara S et al. Obesity and type 2 diabetes have additive effects on left ventricular remodelling in normotensive patients-a cross sectional study. Cardiovasc Diabetol. 2017;16:21.
22. Masugata H Senda S Goda F et al. Echocardiographic assessment of the cardio-renal connection: is left ventricular hypertrophy or diastolic function more closely correlated with estimated glomerular filtration rate in patients with cardiovascular risk factors? Clin Exp Hypertens. 2010;32:113-120.
23. Salazar J Luzardo E Mejías JC et al. Epicardial Fat: Physiological Pathological and Therapeutic Implications. Cardiol Res Pract. 2016;2016:1291537.
24. Parisi V Rengo G Pagano G et al. Epicardial adipose tissue has an increased thickness and is a source of inflammatory mediators in patients with calcific aortic stenosis. Int J Cardiol. 2015;186:167-169.
25. Noyes AM Dua K Devadoss R et al. Cardiac adipose tissue and its relationship to diabetes mellitus and cardiovascular disease. World J Diabetes. 2014;5:868-876.
26. Nasrallah MP Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013;33:54-65.
27. Ortega Moreno L Lamacchia O Copetti M et al. Serum Adiponectin and Glomerular Filtration Rate in Patients with Type 2 Diabetes. PLoS One. 2015;10:e0140631.
28. Puurunen VP Lepojärvi ES Piira OP et al. High plasma leptin levels are associated with impaired diastolic function in patients with coronary artery disease. Peptides. 2016;84:17-21.
29. Dey D Nakazato R Li D et al. Epicardial and thoracic fat - Noninvasive measurement and clinical implications. Cardiovasc Diagn Ther. 2012;2:85-93.
30. Rabkin SW Campbell H. Comparison of reducing epicardial fat by exercise diet or bariatric surgery weight loss strategies: a systematic review and meta-analysis. Obes Rev. 2015;16:406-415.
31. Benedek T Oprincariu D Rat N et al. The Assessment of Epicardial Adipose Tissue in Acute Coronary Syndrome Patients. A Systematic Review. Journal of Cardiovascular Emergencies. 2017;3:18-29.
32. Cardoso AF Furtado MS Grindler J et al. Epicardial Fat Thickness Correlates with P-wave Duration Left Atrial Size and Decreased Left Ventricular Systolic Function in Morbid Obesity. Nutr Metab Cardiovasc Dis. 2017;27:473-582.